Tegsedi
Named-patient access overview. Tegsedi is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
Quick orientation
Tegsedi (inotersen) is a once-weekly subcutaneous antisense oligonucleotide developed approximately by Akcea Therapeutics in collaboration with Ionis Pharmaceuticals and now held by Sobi (Swedish Orphan Biovitrum), with US FDA approval in October 2018 for the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis with polyneuropathy) in adults. Tegsedi works by hybridising to transthyretin mRNA and reducing hepatic synthesis of the disease-causing transthyretin protein.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
How Reserve Meds coordinates Tegsedi
- Patient or treating physician submits an intake at the patient portal.
- Reserve Meds clinical team verifies appropriateness for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific named-patient documentation is prepared.
- Tegsedi is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy with appropriate handling.
Access by country
Reserve Meds publishes a detailed country deep-dive for Tegsedi in every market we coordinate. Each page below covers the destination-country regulatory pathway, real costs, indicative timelines, physician-credential requirements, and handling notes. Tap any country to read the full deep-dive.
Start a request for Tegsedi
Submit a 60-second intake. The clinical team will follow up within 24 hours with case-specific feasibility, timeline, and a formal quote.